Palliativtherapie im Grenzgebiet zwischen Gastroenterologie und (Viszeral-)Chirurgie

 

 Buy Article Permissions and Reprints

Zusammenfassung

Hintergrund: In der Behandlung gastrointestinaler Tumoren wächst die Bedeutung der palliativen Therapie zusehends. Wie auch bei kurativem Ansatz in der Therapie ist eine interdisziplinäre Zusammenarbeit zwischen Gastroenterologen und Chirurgen in der Palliativmedizin anzustreben. Ziel: Anhand häufig auftretender Krankheitsbilder der Palliativmedizin soll das diagnostische und therapeutische Management dieser Erkrankungen erläutert werden. Methode: Komplementäre Kurzübersicht von klinischer Erfahrung und einschlägig recherchierten Referenzen aus dem aktuell-selektiven Schrifttum. Ergebnisse: Der Symptomenkomplex ist heterogen und bedarf genauer differenzialdiagnostischer Vorgehensweisen. Das palliativ-gastroenterologische Vorgehen wird wesentlich vom kompetenten Management des Aszites, der „malignen intestinalen Obstruktion und Obstipation“ (MIO) sowie Nutrition und Schmerz bestimmt. Chirurgisch stehen nach sequenzieller Ausschöpfung von medikamentösen, interventionell-endoskopischen, (teils radiologischen) Maßnahmen die peritoneovenöse Shuntanlage (Aszites), Bypassverfahren (gastroenteral, biliodigestiv, enteroenteral) sowie im Ausnahmefall die Resektion neben der i. v.-Portimplantation oder Korrektur der PEG- / Stentkomplikation im Vordergrund, wobei nach wie vor eine absolute Indikation bei unstillbarer Blutung und Perforation besteht. Diskussion: Mangelnde Studienlage, fehlende Studienergebnisse einschließlich die schwierige Initiierung palliativ-medizinisch ausgerichteter Studien erschweren ein kompetentes evidenzbasiertes Vorgehen, weshalb dieses erheblich von klinischer Erfahrung geprägt ist. Schlussfolgerung: Die effiziente Palliativbetreuung des viszeralmedizinischen Symptomenkomplexes erfordert einschlägige fachspezifische Expertise und interdisziplinäres Handeln aufgrund der nicht seltenen klinischen Fallkonstellationen im Grenzbereich zwischen Gastroenterologie und Chirurgie.

Abstract

Background: In the management of gastrointestinal tumour lesions, palliative treatment has attained an increasing role. As also in curative treatment, an interdisciplinary cooperation between gastroenterologists and surgeons has to be aimed for. Aim: The aim of this study is to illustrate the diagnostic and therapeutic management of frequently occurring diseases in palliative medicine from a gastroenterological point of view. Methods: Complementary short overviews on clinical experience and selectively searched references from the current scientific literature were evaluated. Results: The symptomatic complex is very heterogeneous and requires an adequate approach taking into account the differential diagnosis. The palliative gastroenterological approach is characterised by the competent care on ascites, management of “malignant intestinal obstruction and obstipation” (MIO) as well as appropriate nutrition and analgetic therapy. The surgical approach is indicated after sequential exhaustion of medical, interventional endoscopic and (eventually) image-guided radiological measures; it comprises creation of a peritoneovenous shunt (ascites), bypass procedures (gastroenteral, biliodigestive, enteroenteral) as well as, in extraordinary cases, resection in addition to the implantation of an i. v. port-a-cath or surgical revision of a PEG / stent complication; in particular, in case of recurrent and massive haemorrhage and perforation (absolute indication), surgery becomes necessary. Discussion: A lack of appropriate studies, absence of adequate study results including the difficult initiation of medical studies with palliative intention aggravate a competent evidence-based approach. Therefore, the management is considerably affected by clinical experience. Conclusion: Efficacious care in palliative visceral medicine requires relevant clinical expertise and interdisciplinary action because of the occurrence of clinical cases in gastroenterology at the border to surgery.

Literatur

• 1 Laugsand E A, Kaasa S, de Conno F et al. Intensity and treatment of symptoms in 3030 palliative care patients: a cross-sectional survey of the EAPC Research Network.  J Opioid Manag. 2009;  5 11-21
  PubMedGoogle Scholar
• 2 Teunissen S C, Wesker W, Kruitwagen C et al. Symptom prevalence in patients with incurable cancer: a systematic review.  J Pain Symptom Manage. 2007;  34 94-104
  CrossrefPubMedGoogle Scholar
• 3 Runyon B A, Montano A A, Akriviadis E A et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites.  Ann Intern Med. 1992;  117 215-220
  CrossrefPubMedGoogle Scholar
• 4 Runyon B A, Hoefs J C, Morgan T R. Ascitic fluid analysis in malignancy-related ascites.  Hepatology. 1988;  8 1104-1109
  CrossrefPubMedGoogle Scholar
• 5 Stephenson J, Gilbert J. The development of clinical guidelines on paracentesis for ascites related to malignancy.  Palliat Med. 2002;  16 213-218
  CrossrefPubMedGoogle Scholar
• 6 Polli F, Gattinoni L. Balancing volume resuscitation and ascites management in cirrhosis.  Curr Opin Anaesthesiol. 2010;  23 151-158
  CrossrefPubMedGoogle Scholar
• 7 Gines P, Guevara M, De Las Heras D et al. Review article: albumin for circulatory support in patients with cirrhosis.  Aliment Pharmacol Ther. 2002;  16 Suppl 5 24-31
  PubMedGoogle Scholar
• 8 Cardenas A, Gines P, Runyon B A. Is albumin infusion necessary after large volume paracentesis?.  Liver Int. 2009;  29 636-640 discussion 640–641
  PubMedGoogle Scholar
• 9 Seike M, Maetani I, Sakai Y. Treatment of malignant ascites in patients with advanced cancer: peritoneovenous shunt versus paracentesis.  J Gastroenterol Hepatol. 2007;  22 2161-2166
  CrossrefPubMedGoogle Scholar
• 10 Schumpelick V, Riesener K P. Peritoneovenous shunt--indications, limits, results.  Der Chirurg. 1993;  64 11-15
  PubMedGoogle Scholar
• 11 Becker G, Galandi D, Blum H E. Malignant ascites: systematic review and guideline for treatment.  Eur J Cancer. 2006;  42 589-597
  CrossrefPubMedGoogle Scholar
• 12 Zervos E E, McCormick J, Goode S E et al. Peritoneovenous shunts in patients with intractable ascites: palliation at what price?.  Am Surg. 1997;  63 157-162
  PubMedGoogle Scholar
• 13 Scaringi S, Kianmanesh R, Sabate J M et al. Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: a single western center experience.  Eur J Surg Oncol. 2008;  34 1246-1252
  PubMedGoogle Scholar
• 14 Elias D, Lefevre J H, Chevalier J et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.  J Clin Oncol. 2009;  27 681-685
  CrossrefPubMedGoogle Scholar
• 15 Heiss M M, Murawa P, Koralewski P et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II / III trial.  Int J Cancer. 2010;  127 2209-2221
  CrossrefPubMedGoogle Scholar
• 16 Anthony T, Baron T, Mercadante S et al. Report of the clinical protocol committee: development of randomized trials for malignant bowel obstruction.  J Pain Symptom Manage. 2007;  34 49-59
  CrossrefPubMedGoogle Scholar
• 17 Zorn M, Domagk D, Auerbauch T et al. Malignant bowel obstruction.  Z Gastroenterol. 2010;  48 264-273
  PubMedGoogle Scholar
• 18 Denzer U, Hoffmann S, Helmreich-Becker I et al. Minilaparoscopy in the diagnosis of peritoneal tumor spread: prospective controlled comparison with computed tomography.  Surg Endosc. 2004;  18 1067-1070
  PubMedGoogle Scholar
• 19 Chi D S, Phaeton R, Miner T J et al. A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer.  Oncologist. 2009;  14 835-839
  CrossrefPubMedGoogle Scholar
• 20 Baron T H. Expandable metal stents for the treatment of cancerous obstruction of the gastrointestinal tract.  N Engl J Med. 2001;  344 1681-1687
  CrossrefPubMedGoogle Scholar
• 21 Will U, Thieme A, Fueldner F et al. Treatment of biliary obstruction in selected patients by endoscopic ultrasonography (EUS)-guided transluminal biliary drainage.  Endoscopy. 2007;  39 292-295
  Google Scholar
• 22 Piesman M, Kozarek R A, Brandabur J J et al. Improved oral intake after palliative duodenal stenting for malignant obstruction: a prospective multicenter clinical trial.  Am J Gastroenterol. 2009;  104 2404-2411
  CrossrefPubMedGoogle Scholar
• 23 Havemann M C, Adamsen S, Wojdemann M. Malignant gastric outlet obstruction managed by endoscopic stenting: a prospective single-centre study.  Scand J Gastroenterol. 2009;  44 248-251
  CrossrefPubMedGoogle Scholar
• 24 Gutzeit A, Binkert C A, Schoch E et al. Malignant gastroduodenal obstruction: treatment with self-expanding uncovered wallstent.  Cardiovasc Intervent Radiol. 2009;  32 97-105
  CrossrefPubMedGoogle Scholar
• 25 Larssen L, Medhus A W, Hauge T. Treatment of malignant gastric outlet obstruction with stents: an evaluation of the reported variables for clinical outcome.  BMC Gastroenterol. 2009;  9 45
  CrossrefPubMedGoogle Scholar
• 26 Kim S Y, Song H Y, Kim J H et al. Bridging across the ampulla of Vater with covered self-expanding metallic stents: is it contraindicated when treating malignant gastroduodenal obstruction?.  J Vasc Interv Radiol. 2008;  19 1607-1613
  CrossrefPubMedGoogle Scholar
• 27 Iwamuro M, Kawamoto H, Harada R et al. Combined duodenal stent placement and endoscopic ultrasonography-guided biliary drainage for malignant duodenal obstruction with biliary stricture.  Dig Endosc. 2010;  22 236-240
  CrossrefPubMedGoogle Scholar
• 28 Nguyen-Tang T, Binmoeller K F, Sanchez-Yague A et al. Endoscopic ultrasound (EUS)-guided transhepatic anterograde self-expandable metal stent (SEMS) placement across malignant biliary obstruction.  Endoscopy. 2010;  42 232-236
  Google Scholar
• 29 Topazian M, Baron T H. Endoscopic fenestration of duodenal stents using argon plasma to facilitate ERCP.  Gastrointest Endosc. 2009;  69 166-169
  CrossrefPubMedGoogle Scholar
• 30 Bonin E A, Baron T H. Update on the indications and use of colonic stents.  Curr Gastroenterol Rep. 2010;  12 374-382
  CrossrefPubMedGoogle Scholar
• 31 West M, Kiff R. Stenting of the Colon in Patients with Malignant Large Bowel Obstruction: a Local Experience.  J Gastrointest Cancer. 2010;  [Epub ahead of print]
  PubMedGoogle Scholar
• 32 Slim K, Pirlet I, Millat B. Stenting or not stenting before operating malignant colonic obstruction? That is the question.  Arch Surg. 2010;  145 601-602 author reply 601
  PubMedGoogle Scholar
• 33 Hara K, Yamao K, Mizuno N et al. Endoscopic ultrasound-guided choledochoduodenostomy.  Dig Endosc. 2010;  22 147-150
  CrossrefPubMedGoogle Scholar
• 34 Siddiqui A A, Sreenarasimhaiah J, Lara L F et al. Endoscopic ultrasound-guided transduodenal placement of a fully covered metal stent for palliative biliary drainage in patients with malignant biliary obstruction.  Surg Endosc. 2010;  [Epub ahead of print]
  PubMedGoogle Scholar
• 35 Kim Y S, Gupta K, Mallery S et al. Endoscopic ultrasound rendezvous for bile duct access using a transduodenal approach: cumulative experience at a single center. A case series.  Endoscopy. 2010;  42 496-502
  Google Scholar
• 36 Dittmar Y, Voigt R, Heise M et al. Indikationen und Ergebnisse der palliativen Magenresektion beim fortgeschrittenen Magenkarzinom.  Zentralbl Chir. 2009;  134 77-82
  Article in Thieme ConnectPubMedGoogle Scholar
• 37 Volkmer K, Meyer T, Sailer M et al. PEG-Implantationsmetastase eines Ösophaguskarzinoms Fallbericht und Literaturübersicht.  Zentralbl Chir. 2009;  134 481-485
  Article in Thieme ConnectPubMedGoogle Scholar
• 38 Hisanaga T, Shinjo T, Morita T et al. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction.  Jpn J Clin Oncol. 2010;  40 739-745
  CrossrefPubMedGoogle Scholar
• 39 Mercadante S, Casuccio A, Mangione S. Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review.  J Pain Symptom Manage. 2007;  33 217-223
  CrossrefPubMedGoogle Scholar
• 40 Bennani-Baiti N, Davis M P. Cytokines and cancer anorexia cachexia syndrome.  Am J Hosp Palliat Care. 2008;  25 407-411
  CrossrefPubMedGoogle Scholar
• 41 Tisdale M J. Cancer cachexia.  Curr Opin Gastroenterol. 2010;  26 146-151
  CrossrefPubMedGoogle Scholar
• 42 Angus F, Burakoff R. The percutaneous endoscopic gastrostomy tube. medical and ethical issues in placement.  Am J Gastroenterol. 2003;  98 272-277
  PubMedGoogle Scholar
• 43 Ganga U R, Ryan J J, Schafer L W. Indications, complications, and long-term results of percutaneous endoscopic gastrostomy: a retrospective study.  S D J Med. 1994;  47 149-152
  PubMedGoogle Scholar
• 44 Johnston S D, Tham T C, Mason M. Death after PEG: results of the National Confidential Enquiry into Patient Outcome and Death.  Gastrointest Endosc. 2008;  68 223-227
  CrossrefPubMedGoogle Scholar
• 45 Bauer J D, Capra S. Nutrition intervention improves outcomes in patients with cancer cachexia receiving chemotherapy – a pilot study.  Support Care Cancer. 2005;  13 270-274
  CrossrefPubMedGoogle Scholar

Dr. F. Meyer

Universitätsklinikum Magdeburg · Klinik für Allgemein-, Viszeral- und Gefäßchirurgie

Leipziger Straße 44

39120 Magdeburg

Deutschland

Phone: +49 / (0)3 91 / 6 71 55 00

Fax: +49 / (0)3 91 / 6 71 55 70

Email: frank.meyer@med.ovgu.de